148,040 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 148,040 shares of the medical research company's stock, valued at approximately $29,091,000. Proficio Capital Partners LLC owned 0.08% of IQVIA at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Impax Asset Management Group plc increased its holdings in shares of IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after purchasing an additional 157,809 shares during the period. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after purchasing an additional 196 shares during the period. Covestor Ltd increased its holdings in shares of IQVIA by 34.4% in the third quarter. Covestor Ltd now owns 246 shares of the medical research company's stock worth $59,000 after purchasing an additional 63 shares during the period. Apollon Wealth Management LLC increased its holdings in shares of IQVIA by 9.6% in the third quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company's stock worth $1,155,000 after purchasing an additional 427 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of IQVIA in the third quarter worth $230,000. Institutional investors own 89.62% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Citigroup cut their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Trading Up 1.9 %

Shares of IQVIA stock traded up $3.55 during trading on Tuesday, reaching $188.45. 1,344,794 shares of the stock were exchanged, compared to its average volume of 1,226,685. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock's fifty day moving average is $196.34 and its 200 day moving average is $209.96. The firm has a market cap of $33.23 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $256.34.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.